Clinical Utility of Tumor Next-Generation Sequencing Panel Testing to Inform Treatment Decisions for Patients With Advanced Solid Tumors in a Tertiary Care Center.
Lucia Bogdan, Ramy R Saleh, Lisa Avery...
https://pubmed.ncbi.nlm.nih.gov/38935894/Actively Recruiting
Led by University Health Network, Toronto · Updated on 2026-06-05
10000
Participants Needed
7
Research Sites
N/A
Total Duration
Researchers are investigating the use of targeted gene sequencing to better understand advanced, incurable solid tumors in patients receiving standard palliative treatments. The study aims to collect biomarker data from previously collected tumor samples to help guide future treatment decisions and identify suitable clinical trials. This research also seeks to develop a province-wide registry of gene sequencing results and a biobank of tumor and blood samples to support cancer research in Ontario. Participants will provide archival formalin-fixed paraffin embedded FFPE tumor tissue for targeted next generation sequencing NGS panel testing. Additional tumor tissue and blood samples will be collected for future research and stored in a centralized biorepository. The results of selected gene tests will be shared securely with the treating oncologist through a web portal. Remaining tumor DNA and blood samples may undergo further analysis to support test development and research. During the study, participants health records will be reviewed and linked to health databases to gather information about their medical treatments and outcomes. Researchers will monitor how gene sequencing data is used in clinical care and research, including the number of patients included in the registry and biobank. The study will last for several years, with ongoing collection and analysis of data to improve understanding of cancer and its treatment.
CONDITIONS
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
S
Samanta Del Rossi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Health Network, Toronto
Lead Sponsor
Princess Margaret Hospital, Canada
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants with advanced solid tumors who are receiving standard palliative treatments are observed while archival tumor tissue and blood samples are collected for targeted next generation sequencing and future research.
Single visit for sample collection; follow-up assessments occur through medical record review and data collection
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Lucia Bogdan, Ramy R Saleh, Lisa Avery...
https://pubmed.ncbi.nlm.nih.gov/38935894/Lucy X Ma, Osvaldo Espin-Garcia, Philippe L Bedard...
https://pubmed.ncbi.nlm.nih.gov/35262412/Coralea Kappel, Di Maria Jiang, Bryan Wong...
https://pubmed.ncbi.nlm.nih.gov/35337750/University Health Network, Toronto
Lead Sponsor
Princess Margaret Hospital, Canada
Collaborating Sponsor